GlassScriptPhysician profile
Matthew James Mccall
NPI 1366648164
$6,264.09
in general payments reported to CMS, 2019-2025
23 companies · $1,639 in 2025
The $1,639 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $133 · 2021: $492 · 2022: $755 · 2023: $1,170 · 2024: $1,190 · 2025: $1,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,954 · Education: $44.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,953.53 |
| Education | $44.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,056.26 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $949.40 | 2019-2025 | Biktarvy, Veklury |
| Merck Sharp & Dohme LLC | $653.36 | 2019-2025 | Pifeltro, Delstrigo, Zerbaxa |
| Astellas Pharma US INC | $446.29 | 2019-2025 | Cresemba |
| Paratek Pharmaceuticals, INC. | $365.89 | 2020-2025 | Nuzyra |
| Insmed, INC. | $330.11 | 2019-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $328.72 | 2019-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Abbvie INC. | $318.21 | 2021-2025 | |
| Theratechnologies INC. | $280.82 | 2019-2025 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $213.16 | 2019-2025 | Mytesi |
| La Jolla Pharmaceutical Company | $208.86 | 2022-2025 | Xerava, Zevtera |
| Ferring Pharmaceuticals INC. | $172.77 | 2023-2024 | Rebyota |
| Janssen Biotech, INC. | $156.20 | 2019-2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $143.78 | 2023-2025 | Cuvitru |
| Shionogi INC | $127.65 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $112.05 | 2019-2025 | |
| Pfizer INC. | $100.84 | 2022-2025 | |
| Csl Behring | $82.22 | 2019-2023 | Hizentra |
| Allergan, INC. | $82.14 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $77.54 | 2025 | Vibativ |
| Shire North American Group INC | $27.88 | 2019 | |
| Mylan Pharmaceuticals INC. | $18.02 | 2019 | |
| Sanofi Pasteur INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.